Jin Medical International Ltd. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of May 2025 for Jin Medical International Ltd., a foreign private issuer headquartered in Changzhou City, China. The report discloses a regulatory notice received from The Nasdaq Stock Market LLC regarding listing compliance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing deficiency notice and contains no financial performance data.
Material Changes
The primary material event is the receipt of a deficiency letter from Nasdaq on May 2, 2025. The Company failed to maintain the minimum bid price of $1.00 per share for its Ordinary Shares over the 30 consecutive business days between March 20, 2025, and May 1, 2025, violating Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-calendar-day compliance period ending October 29, 2025, to regain compliance.
- Remediation Options: Compliance can be achieved if the closing bid price reaches or exceeds $1.00 per share for 10 consecutive business days. Alternatively, the Company may implement a reverse stock split, which must be completed no later than ten business days prior to October 29, 2025.
- Delisting Risk: If the Company fails to regain compliance during the initial period, it may be eligible for a second 180-day period if it meets other listing standards. Failure to cure the deficiency ultimately subjects the securities to delisting.
- Management Stance: Management intends to actively monitor the share price and evaluate options to regain compliance but explicitly states there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of Jin Medical International Ltd. Ordinary Shares to assess proximity to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split before the October 2025 deadline.
- Review the attached Press Release (Exhibit 99.1) for additional details on the Company's specific remediation strategy.
- Check subsequent filings for updates on the compliance status or potential delisting notices.